<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Lab Physicians</journal-id><journal-id journal-id-type="iso-abbrev">J Lab Physicians</journal-id><journal-id journal-id-type="publisher-id">JLP</journal-id><journal-title-group><journal-title>Journal of Laboratory Physicians</journal-title></journal-title-group><issn pub-type="ppub">0974-2727</issn><issn pub-type="epub">0974-7826</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">3574496</article-id><article-id pub-id-type="publisher-id">JLP-4-120</article-id><article-id pub-id-type="doi">10.4103/0974-2727.105594</article-id><article-categories><subj-group subj-group-type="heading"><subject>How I do it?</subject></subj-group></article-categories><title-group><article-title>Rapid Identification and Drug Susceptibility Testing of <italic>Mycobacterium tuberculosis</italic>: Standard Operating Procedure for Non-Commercial Assays: Part 3: Colorimetric Redox Indicator Assay v1.3.12</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Singh</surname><given-names>Sarman</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Kumar</surname><given-names>Parveen</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sharma</surname><given-names>Shreya</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mumbowa</surname><given-names>Francis</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Martin</surname><given-names>Anandi</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Durier</surname><given-names>Nicolas</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Laboratory Medicine, Division of Clinical Microbiology, All India Institute of Medical Sciences, New Delhi, India</aff><aff id="aff2"><label>2</label>Department of Medical Microbiology, School of Biomedical Sciences, Makerere University College of Health Sciences, Kampala, Uganda</aff><aff id="aff3"><label>3</label>Department of Biochemistry and Microbiology, Ghent University, Belgium</aff><aff id="aff4"><label>4</label>Culture and Drug Susceptibility Testing Subgroup, New Diagnostic Working Group, Stop TB Partnership, Geneva, Switzerland</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Prof. Sarman Singh, E-mail: <email xlink:href="sarman_singh@yahoo.com">sarman_singh@yahoo.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Jul-Dec</season><year>2012</year></pub-date><volume>4</volume><issue>2</issue><fpage>120</fpage><lpage>126</lpage><permissions><copyright-statement>Copyright: &#x000a9; Journal of Laboratory Physicians</copyright-statement><copyright-year>2012</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>The previous two standard operating procedures (SOPs) related to the culture and drug susceptibility testing (DST) of <italic>Mycobacterium tuberculosis</italic> with the microscopic observation drug susceptibility assay (Part 1) and nitrate reductase assay (Part 2). The present SOP is devoted to a third non-commercial culture and DST method known as colorimetric redox indicator assay (CRI). As its name indicates, the CRI detects the ability of the <italic>M. tuberculosis</italic> to reduce the colored oxidation-reduction indicator when added to a liquid culture of <italic>M. tuberculosis</italic>, after exposing the growth to different anti-mycobacterial drugs. The change in the color of the indicator denotes the proportionate number of viable Mycobacteria in the medium. The identification and DST results can be obtained in 7-8 days. This SOP document has been developed through the culture and DST subgroup of the STOP tuberculosis (TB) Partnership New Diagnostic Working Group. It is intended for laboratories that would want to use or already use this rapid non-commercial method for culture identification and DST of <italic>M. tuberculosis</italic>, notably in resource-constraint settings in Asia and Africa.</p></abstract><kwd-group><kwd>Mycobacterium</kwd><kwd>tuberculosis</kwd><kwd>drugs</kwd><kwd>susceptibility</kwd><kwd>testing</kwd><kwd>training</kwd></kwd-group></article-meta></front><body><sec id="sec1-1"><title>INTRODUCTION</title><sec id="sec2-1"><title>Scope</title><p>This standard operating procedure (SOP) document has been specially compiled for the implementation of non-commercial culture and drug susceptibility testing (DST) methods endorsed by New Diagnostic Working Group-STOP tuberculosis (TB) Partnership (WHO) for laboratory network performing the rapid non-commercial rapid culture identification and DST testing for <italic>Mycobacterium tuberculosis</italic> and intended for the use of TB diagnostic laboratories, located in various Asian countries. It is also intended as a companion to the TB laboratory training manuals.</p><p>This SOP describes the procedure for the colorimetric redox indicator (CRI) assay methods for <italic>M. tuberculosis</italic> isolates grown from conventional culture. This indirect method is based on the reduction of a colored indicator added to liquid culture medium on a microtiter plate after <italic>in vitro</italic> exposure of<italic>M. tuberculosis</italic> isolates to anti-TB drugs. The time for diagnosis of multidrug resistant ( MDR) is faster than other conventional phenotypic DST methods in liquid culture. The rapid detection of <italic>M. tuberculosis</italic> and information about DST allows proper management of TB.</p><p>As suspensions with viable, infectious bacteria are handled, strict compliance with safety and protection measures is mandatory. The procedure must be carried out in a laboratory, meeting WHO standards for biosafety level two with access restricted to authorized personnel only.</p></sec><sec id="sec2-2"><title>Purpose</title><p>The purpose of this SOP is to rapidly provide clinicians with information about the patients suspected to have MDR <italic>M. tuberculosis</italic> for proper clinical management.</p></sec><sec id="sec2-3"><title>Personnel qualifications</title><p>The test performer should be having a diploma in laboratory technologies and preferably university graduate in biological sciences with sufficient experience.</p></sec><sec id="sec2-4"><title>Medical fitness</title><p>In accordance with national laws and practices, arrangements should be made for an appropriate health surveillance of TB laboratory workers:</p><p><list list-type="bullet"><list-item><p>Before enrolment in the TB laboratory</p></list-item><list-item><p>At regular intervals thereafter, annually or bi-annually</p></list-item><list-item><p>After any biohazard incident</p></list-item><list-item><p>In case of onset of TB symptoms</p></list-item></list>
</p><p>All cases of disease or death identified in accordance with national laws and/or practice as resulting from occupational exposure to biological agents shall be notified to the competent authority.</p><sec id="sec3-1"><title>Education and training</title><p>Personnel are required to be knowledgeable about the procedures in this SOP. Documentation of training and familiarization with this SOP can be found in the training file for each employee.</p><p>The laboratory staff shall confirm (i.e., documentation in the training file of familiarization with the SOP) that they can properly perform the procedure before commencing work. Education and training must be given on the following topics:</p><p>
<list list-type="bullet"><list-item><p>Potential risks to health (symptoms of TB disease and transmission)</p></list-item><list-item><p>Precautions to be taken to minimize aerosol formation and prevent exposure</p></list-item><list-item><p>Hygiene requirements</p></list-item><list-item><p>Wearing and use of protective equipment and clothing</p></list-item><list-item><p>Handling of potentially infectious materials</p></list-item><list-item><p>Laboratory design, including airflow conditions</p></list-item><list-item><p>Use of biological safety cabinets (BSCs) (operation identification of malfunctions, maintenance)</p></list-item><list-item><p>Use of autoclaves, incubators (operation, identification of malfunctions, maintenance)</p></list-item><list-item><p>Prevention of incidents and steps to be taken by workers in case of incidents (biohazard incidents, chemical, electrical and fire hazards)</p></list-item><list-item><p>Good laboratory practice and good microbiological techniques</p></list-item><list-item><p>Organization of workflow and procedures</p></list-item><list-item><p>Waste management</p></list-item><list-item><p>Importance of laboratory results for patient management</p></list-item><list-item><p>Importance of laboratory results for the national TB program</p></list-item><list-item><p>Training shall be given before a staff member takes up his or her post</p></list-item><list-item><p>Repeat training periodically, preferably every year</p></list-item></list>
</p></sec></sec><sec id="sec2-5"><title>Bio-safety precautions in tuberculosis laboratory</title><p>TB laboratory should have all the major requirements and facility for handling <italic>M. tuberculosis</italic> safely, and involves minimum risk to the laboratory personnel, if they take proper precautions, and employ proper techniques described in these SOPs. Laboratory safety involves all the procedures and methods one needs to follow to minimize the risks of laboratory acquired infections. Use of laboratory is limited to trained TB lab personnel.</p><sec id="sec3-2"><title>Biological safety cabinets</title><p>
<list list-type="bullet"><list-item><p>Switch ON the safety cabinets for at least 30 min before use. Note that the reading on the mini gauge pressure is satisfactory</p></list-item><list-item><p>Wear double pair of gloves, every time you work inside the cabinet</p></list-item><list-item><p>Biosafety cabinets need to be cleaned with 5% phenolic or 1% hypochlorite solution before work</p></list-item><list-item><p>Keep disposal bin/vessel with 5% phenolic or 5% hypochlorite disinfects inside the cabinet at the right side corner</p></list-item><list-item><p>Wipe of gauge-cloth soaked in 5% phenolic or 5% hypochlorite, should be readily available inside the cabinet</p></list-item><list-item><p>Arrange all un-infected material required towards the left side</p></list-item><list-item><p>All the processed samples need to be arranged right side</p></list-item><list-item><p>Do not process more than six specimens at a time, inside the cabinet.</p></list-item><list-item><p>After completion of work, wipe off the surface with 5% phenolic solution, and discard all wipes in biohazard bags, or in disposal container meant for infectious materials</p></list-item><list-item><p>Discard off the outer glove, too, inside the bio-safety cabinet</p></list-item><list-item><p>Wipe off the inner glove with disinfectant before touching anything else in the lab</p></list-item></list>
</p></sec><sec id="sec3-3"><title>Waste disposal and handling</title><p>All infectious waste should be discarded in the bio-safety disposal bin. All infectious solid waste-wipes, swabs, plastic, paper towels, gauze pads, gloves, etc., should be placed inside the double autoclave bags, sealed with autoclave tape and sterilized at 121&#x000b0;C for 30 min in the autoclave.</p><p>Liquid waste, in the steel discarding bins, should be disinfected in 5% phenol for at least 1 h, before sealing the caps and autoclaved at 121&#x000b0;C for 30 min.</p></sec><sec id="sec3-4"><title>Accidents and spillages</title><p>
<list list-type="roman-lower"><list-item><p><bold>Spills inside BSC</bold></p><p>All workers using the BSC should keep absorbent materials (gauge cloth/adsorbent sheet) and 5% phenol within the cabinet.</p><p>
<list list-type="bullet"><list-item><p>Alert all people in the adjacent laboratories in the event of spill</p></list-item><list-item><p>Spread 5% phenol soaked wipe immediately, while the BSC continues to operate. Wait for 15-20 min.</p></list-item><list-item><p>Use paper towels to wipe up the spill, working from the edges into the center</p></list-item><list-item><p>Decontaminate equipment: Items that are not readily or easily surface decontaminated should be carefully placed into autoclave bags and removed for further treatment (e.g., decontamination by autoclaving)</p></list-item><list-item><p>Contaminated gloves and clothes (sleeves are most likely to be contaminated); remove and decontaminate the lab coat by autoclaving or soaking in decontaminant.</p></list-item></list>
</p></list-item><list-item><p><bold>Spills outside containment room in the BSC</bold></p><p>Spills on equipment (such as vortex, centrifuge, incubator, refrigerator etc.), laboratory benches, walls or floors:</p><p>
<list list-type="bullet"><list-item><p>Immediately indicate to all personnel working in the lab, and evacuate for 1 h to allow dissipation of aerosols created by the spill (negative air pressure system would clear the aerosols)</p></list-item><list-item><p>Leave the BSC operating and cultures inside cabinet</p></list-item><list-item><p>Leave the containment facility following exit procedures</p></list-item><list-item><p>Close laboratory doors and post warning signs to prevent others from entering the laboratory</p></list-item><list-item><p>Thoroughly wash hands and other apparently contaminated areas with soap and water. Put on clean disposable gloves</p></list-item><list-item><p>If personal clothing is contaminated, remove all outer clothing and place it in the autoclave or container for autoclaving. Put on clean garments</p></list-item><list-item><p>Upon returning to the laboratory wear the N95 mask, fresh lab coat and double pair gloves to start decontamination, cover the spill area with paper towels soaked in 5% phenol solution or 1:10 dilution of 20% bleach (freshly prepared), or 70% ethanol solution (Do not pour decontamination solution directly onto the spill in order to avoid additional release of aerosols)</p></list-item><list-item><p>Let it stand for 20 min then wipe up with paper towels</p></list-item><list-item><p>Wipe up the spill with the soaked paper towels and place the used towels in an autoclave bag and autoclave</p></list-item><list-item><p>Place gloves and paper towels in autoclave bag and autoclave</p></list-item><list-item><p>Spill inside the centrifuge bucket/tube: Always use the aerosol containment cups for centrifuging. Always open the centrifuge buckets inside the bio-safety cabinet. Autoclave the buckets</p></list-item><list-item><p>Wash hands and other apparently contaminated areas again with soap and water</p></list-item></list>
</p></list-item><list-item><p><bold>Dont's</bold></p><p>
<list list-type="bullet"><list-item><p>Eating, drinking, smoking, applying cosmetics, use of mobile phones, or applying contact lenses in the TB laboratory</p></list-item><list-item><p>Don't allow unauthorized personnel to enter the TB laboratory</p></list-item><list-item><p>Mouth pipetting</p></list-item><list-item><p>Crowding of lab with material that is not required inside</p></list-item></list>
</p></list-item></list>
</p></sec></sec></sec><sec id="sec1-3"><title>PROCEDURE</title><sec id="sec2-6"><title>Principle</title><p>Colorimetric methods for detecting drug resistance in <italic>M. tuberculosis</italic> are based on the reduction of an oxidation-reduction indicator added to a liquid culture medium after <italic>M. tuberculosis</italic> has been exposed <italic>in vitro</italic> to different antibiotics. Resistance is detected by a change in color of the oxidation-reduction indicator, which is directly proportional to the number of viable mycobacteria in the medium.</p></sec><sec id="sec2-7"><title>Samples</title><p>Pure cultures of acid - fast bacilli grown on solid media and liquid medium are used for indirect microscopic observation drug susceptibility assay.</p><p>Confirm the growth as <italic>M. tuberculosis</italic> using mycobacterial antigen 64(MPT64), p-nitro benzoic acid (PNB) or any other standard methods being practiced in the local laboratory.</p></sec><sec id="sec2-8"><title>Equipment and materials</title><p>
<list list-type="bullet"><list-item><p>7H9 broth: Middlebrook 7H9 (Becton Dickinson ref. 271310)</p></list-item><list-item><p>Oleic acid dextrose catalase (OADC) (10 &#x000d7; 20 ml Becton Dickinson ref. 211886)</p></list-item><list-item><p>Glycerol (Merck ref. 356350)</p></list-item><list-item><p>Casitone (pancreatic digest casein Bacto Casitone 225930 BD)</p></list-item><list-item><p>96-well plate with lid: (box of 50 plate-Becton Dickinson ref. 353072)</p></list-item><list-item><p>Filter 0.2 &#x003bc;m: Acrodisc Syringe filter (50 filters-Pall Life Sciences ref. 4652)</p></list-item><list-item><p>Syringes for filter: 2 or 5 ml</p></list-item><list-item><p>Distilled water (DW)</p></list-item><list-item><p>37&#x000b0;C incubator</p></list-item><list-item><p>Micropipettes: 1000 &#x003bc;l/200 &#x003bc;l</p></list-item><list-item><p>Tips + tips with filter (1000 &#x003bc;l/200 &#x003bc;l)</p></list-item><list-item><p>Multichannel pipette</p></list-item><list-item><p>Resazurin dye: Resazurin sodium salt (Sigma
<sup>&#x000ae;</sup>, USA, ref. R 7017)</p></list-item><list-item><p>Analytic balance</p></list-item><list-item><p>Incubator 37&#x000b0;C</p></list-item><list-item><p>Autoclave</p></list-item><list-item><p>Drugs for MDR screening: Rifampicin (RIF) (Sigma, ref. R7382), i soniazid (INH) (Sigma, ref. I3377)</p></list-item></list>
</p></sec><sec id="sec2-9"><title>Reagents and solutions preparation</title><p>
<list list-type="bullet"><list-item><p>7H9 medium with supplement (7H9-S) = 7H9 broth +10% OADC +0.5% glycerol +0.1% casitone</p></list-item><list-item><p>For 200 ml of 7H9-S medium:</p><p>
<list list-type="simple"><list-item><label>&#x02666;</label><p>Weigh 0.94 g of 7H9 powder and dissolve in 180 ml of DW; mix until complete solubilization</p></list-item><list-item><label>&#x02666;</label><p>Weigh 0.2 g of casitone and add to the previous solution until complete solubilization. Warm the solution if necessary</p></list-item><list-item><label>&#x02666;</label><p>Autoclave the broth in a 250 ml flask</p></list-item><list-item><label>&#x02666;</label><p>After autoclaving and cooling, add 20 ml of OADC enrichment and 1 ml of sterile glycerol. Mix well</p></list-item><list-item><label>&#x02666;</label><p>Check in the incubator for sterility (leave one night in the incubator and check the day after if there is no turbidity and if the media is still transparent)</p></list-item><list-item><label>&#x02666;</label><p>Store the medium protected from direct light at 4&#x000b0;C</p></list-item></list>
</p></list-item></list>
</p></sec><sec id="sec2-10"><title>Drug stock solutions</title><p>
<list list-type="bullet"><list-item><p>INH: Weigh 2 mg of INH powder and dissolve in 2.0 ml of DW, making a stock solution of 1 mg/ml. Sterilize by filtration with a 0.22 &#x003bc;m syringe filter; aliquot (30 &#x003bc;l) and store frozen (&#x02212;20&#x000b0;C) until use.</p></list-item><list-item><p>RIF: Weigh 20 mg of RIF powder, dissolve in 2.0 ml of absolute methanol, making a stock solution of 10 mg/ml. Sterilize by filtration with a 0.22 &#x003bc;m syringe filter; aliquot and store frozen (&#x02212;20&#x000b0;C) until use (300 &#x003bc;l) 
[<xref ref-type="table" rid="T1">Table 1</xref>].</p></list-item></list></p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Preparation of drug stock and working solutions</p></caption><graphic xlink:href="JLP-4-120-g001"/></table-wrap></sec><sec id="sec2-11"><title>Drug working solutions</title><p>For the preparation working solutions of drugs, take the amount of drug stock solution and dilute into 7H9-S medium as per the amount given in 
<xref ref-type="table" rid="T1">Table 1</xref>.</p></sec><sec id="sec2-12"><title>Drugs storage</title><p>Drug solutions may be frozen in aliquots at &#x02212;20&#x000b0;C and stored for up to 3 months. Once thawed, discard the leftover and do not store or refreeze. To avoid wastage of drugs during the freeze/thaw processes make the drugs aliquot as per the amount required at a time.</p></sec><sec id="sec2-13"><title>Preparation of inoculum</title><sec id="sec3-5"><title>Inoculum from growth on solid medium</title><p>It is very important to have fresh growth on a solid medium. Older cultures may result in unreliable susceptibility test results.</p><p>
<list list-type="bullet"><list-item><p>Take a loop full of bacterial growth with a sterile loop and put it in a sterile vial with glass beads just covering the bottom of the vial with 2.5 ml of 7H9-S broth (try not to take any medium when removing growth)</p></list-item><list-item><p>Vortex the vial for at least 1 min to break the clumps until a fairly turbid suspension is obtained</p></list-item><list-item><p>Allow it to stand for 5 min</p></list-item><list-item><p>Transfer the supernatant to a new sterile vial and leave it to sediment for 15 min</p></list-item><list-item><p>Transfer the supernatant to a new sterile vial</p></list-item><list-item><p>Compare the turbidity of the suspension using the scale McFarland 1.0 standard</p></list-item><list-item><p>Set the turbidity of inoculum as per McFarland 1.0 standard using 7H9-S</p></list-item><list-item><p>Make a 1:20 dilution of inoculum with 7H9-S broth</p></list-item></list>
</p></sec><sec id="sec3-6"><title>Inoculum from a liquid medium</title><p>
<list list-type="bullet"><list-item><p>Transfer 2.5 ml of the pellet of culture to a sterile vial containing glass beads</p></list-item><list-item><p>Vortex for at least 1 min until a fairly turbid suspension is obtained</p></list-item><list-item><p>Allow it to stand for 5 min</p></list-item><list-item><p>Transfer the supernatant to a new sterile vial and leave it to sediment for 15 min</p></list-item><list-item><p>Transfer the supernatant to a new sterile vial</p></list-item><list-item><p>Compare the turbidity of the suspension using the scale McFarland 1.0 standard</p></list-item><list-item><p>Set the turbidity of inoculum as per McFarland 1.0 standard using 7H9-S</p></list-item><list-item><p>Make a 1:20 dilution of inoculum with 7H9-S broth</p></list-item></list>
</p></sec></sec><sec id="sec2-14"><title>Colorimetric redox indicator assay plate setting up for the multidrug resistant screening</title><p>Refer to the diagram of the 96 well microtiter plate [<xref ref-type="fig" rid="F1">Figure 1</xref>].</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Colorimetric redox indicator assay plate setting up for first line drugs (I: Isoniazid and R: Rifampicin) GC positive control can be done in duplicate for each isolate (Isol B10 and B11: +Isol A; C10 and C11: GC+Isol. B; D10 and D11 G+H<sub>37</sub> Rv; E10 and E11 GC+ Multi drug resistant, F10-F11 will be the GC (-)</p></caption><graphic xlink:href="JLP-4-120-g002"/></fig><p>In a 96-well flat-bottom microtiter plate (with cover, BD) there is enough space to test four isolates against the two drugs- INH and RIF, in six 2-fold dilutions of each drug.</p><p>
<list list-type="bullet"><list-item><p>Add 100 &#x003bc;l of 7H9-S broth to all wells of the columns 2-11 from rows B to G</p></list-item><list-item><p>Add 100 &#x003bc;l of the working solution of INH to wells B2, B4, B6, and B8</p></list-item><list-item><p>Add 100 &#x003bc;l of the working solution of RIF to wells B3, B5, B7, and B9</p></list-item><list-item><p>With a multi-channel pipette make two fold serial dilutions (transfer 100 &#x003bc;l) from rows B to G (columns 2-9) discarding the last 100 &#x003bc;l after mixing in row G</p></list-item><list-item><p>Add 100 &#x003bc;l of 7H9-S broth to wells B11-E11; these will represent the negative and sterility controls on</p></list-item><list-item><p>the test</p></list-item><list-item><p>Inoculate plate with 100 &#x003bc;l of final culture suspension in respective culture wells including its respective growth control (GC) (+)</p></list-item><list-item><p>Add 200 &#x003bc;l of sterile DW to all the outer wells left without broth; these will prevent evaporation during incubation of the plate.</p></list-item><list-item><p>Cover the plate with lid, seal properly with parafilm from all sides or in zip lock bags and incubate at 37&#x000b0;C for 7 days. (Note: For each batch 1 set of quality control (QC) (1 H<sub>37</sub>Rv and 1 MDR) is run; if QC is not being run on the same plate in that case replace H<sub>37</sub>Rv and MDR with isolate C and D, respectively)</p></list-item></list>
</p></sec><sec id="sec2-15"><title>Preparation of resazurin dye</title><p>Prepare a resazurin solution at 0.02% in sterile DW, sterilized by 0.2 &#x003bc;m syringe filter. The dye solution must be stored in dark at 4&#x000b0;C for 2 weeks.</p></sec><sec id="sec2-16"><title>Color development and interpretation of results</title><p>After 7 days incubation, the plates are taken from the incubator and 30 &#x003bc;l of the resazurin dye solution is added to all the wells and the plate again sealed and incubated overnight for color development.</p><p>A change in color from blue to pink means a growth of the isolates at that concentration of the drug. For better interpretation of the results, the color must be compared to the color present in the GC well.</p><sec id="sec3-7"><title>The minimal inhibitory concentration</title><p>Minimal inhibitory concentration (MIC) of each drug is interpreted as the lowest concentration of the antibiotic that prevents a change in color of the resazurin dye. MIC values are scored for each isolate for comparison with the results obtained with the proportion method.</p></sec><sec id="sec3-8"><title>Positive and negative controls</title><p>The positive control should show positive growth and the negative control (NC) should show no growth within the incubation protocol period. If NC shows a growth, investigate procedures, could be a cross-manipulation and check all reagents for possible source of contamination.</p></sec><sec id="sec3-9"><title>Breakpoint concentration</title><p>The isolate is considered as resistant isolate, which showed MIC values either equal to or higher than the given in <xref ref-type="table" rid="T2">Table 2</xref> against the INH and RIF drugs.</p><p>Refer to the [<xref ref-type="fig" rid="F2">Figure 2</xref>] and [<xref ref-type="table" rid="T3">Table 3</xref>] for the better interpretation of the results 
[<xref ref-type="table" rid="T2">Table 2</xref>].</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>Demonstration of colorimetric redox indicator assay plate, refer to <xref ref-type="table" rid="T3">Table 3</xref> for result interpretation</p></caption><graphic xlink:href="JLP-4-120-g003"/></fig><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Breakpoint concentration</p></caption><graphic xlink:href="JLP-4-120-g004"/></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Interpretation and results of colorimetric redox indicator assay plate demonstrated in <xref ref-type="fig" rid="F2">Figure 2</xref></p></caption><graphic xlink:href="JLP-4-120-g005"/></table-wrap></sec></sec><sec id="sec2-17"><title>Detection of contamination</title><p>The incidence of contamination varies from laboratory to laboratory depending on several factors. The recommendation is that up to 5% contamination rate is acceptable. Liquid media are more susceptible to contamination than solid media. It is extremely important to take care during the manipulation and to work with sterile material.</p><p>
<list list-type="bullet"><list-item><p>Any well with a turbid appearance is suspected of contamination and result of this well is not valid</p></list-item><list-item><p>At the moment that you add the resazurin dye if you observe directly a change of color the well could be contaminated and has to be discarded</p></list-item></list>
</p><sec id="sec2-18"><title>Precautions</title><p>
<list list-type="bullet"><list-item><p>All work should be carried out in a proper BSC (class II)</p></list-item><list-item><p>All materials should be sterilized by autoclaving prior to disposal</p></list-item><list-item><p>Plate should be kept in the incubator in a box to avoid that someone moved the plate by accident</p></list-item><list-item><p>Plate should be closed on both sides by a small tape for security</p></list-item></list>
</p></sec><sec id="sec2-19"><title>Quality control</title><p>It is important to perform a quality control (QC) of DST for first-line drugs testing. Add the standard isolate of <italic>M. tuberculosis</italic> (H 
<sub>37</sub>Rv). Preferably, a drug-resistant strain should also be included into the QC. If the susceptible H<sub>37</sub>Rv shows some resistance, then all the results obtained within during the experiment become invalid and the test should be repeated.</p></sec></sec></sec><sec id="sec1-4"><title>FURTHER READING</title><p>
<list list-type="order"><list-item><p>Martin A, Palomino JC. Procedure manual colorimetric redox indicator (CRI) for drug susceptibility testing for<italic>M. tuberculosis</italic> [Internet], version 06-2012. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.tbevidence.org">http://www.tbevidence.org</ext-link>. [Last accessed date on 4 Feb 2012]</p></list-item><list-item><p>Martin A, Morcillo N, Lemus D, Montoro E, Telles MA, Simboli N, <italic><italic>et al</italic></italic>. Multicenter study of MTT and resazurin assays for testing susceptibility to first-line anti-tuberculosis drugs. Int J Tuberc Lung Dis 2005;9:901-6.</p></list-item><list-item><p>Martin A, Portaels F, Palomino JC. Colorimetric redox-indicator methods for the rapid detection of multidrug resistance in <italic>Mycobacterium tuberculosis</italic>: A systematic review and meta-analysis. J Antimicrob Chemother 2007;59:175-83.</p></list-item><list-item><p>Sankar MM, Gopinath K, Singla R, Singh S. <italic>in-vitro</italic> antimycobacterial drug susceptibility testing of non-tubercular mycobacteria by tetrazolium microplate assay. Ann Clin Microbiol Antimicrob 2008;7:15.</p></list-item><list-item><p>World Health Organization. Non-commercial culture and drug-susceptibility testing methods for screening of patients at risk of multi-drug resistant tuberculosis: Policy statement, July, 2010. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/tb/dots/laboratory/whopolicy_noncommercialculture_and_dstmethods_july10.pdf">http://www.who.int/tb/dots/laboratory/whopolicy_noncommercialculture_and_dstmethods_july10.pdf</ext-link>. [Last accessed date on 11 Nov. 2012]</p></list-item></list>
</p></sec></body><back><ack><title>ACKNOWLEDGMENT</title><p>The authors would like to thank Dr. Alessandra Varga of FIND for her administrative support to this project, to Dr. David Moore for his technical inputs in the preparation and finalization of this SOP and all core members of the new diagnostic working group (NDWG) for approving this project.</p></ack><fn-group><fn fn-type="supported-by"><p><bold>Source of Support:</bold> Culture and drug susceptibility testing subgroup,
Stop-TB Partnership, WHO &#x00026; FIND, Geneva, Switzerland</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> None declared.</p></fn></fn-group></back></article>